Abstract. Quantitative prediction of the impact of chronic kidney disease (CKD) on drug disposition has become important for the optimal design of clinical studies in patients. In this study, clinical data of 151 compounds under CKD conditions were extensively surveyed, and alterations in pharmacokinetic parameters were evaluated. In CKD patients, the unbound hepatic intrinsic clearance decreased to a similar extent for drugs eliminated via hepatic metabolism by cytochrome P450, UDP-glucuronosyltransferase, and other mechanisms. Renal clearance showed a similar decrease to glomerular filtration rate, irrespective of the contribution of tubular secretion. The scaling factor (SF) obtained from the interquartile range of the relative change in each parameter was applied to the well-stirred model to predict clearance in patients. Hepatic and renal clearance could be successfully predicted for approximately half and two-thirds, respectively, of the applied compounds, showing the high utility of SFs. SFs were also introduced to a physiologically based pharmacokinetic (PBPK) model, and the plasma concentration profiles of 12 model compounds with different elimination pathways were predicted for CKD patients. The PBPK model combined with SFs provided good predictability for plasma concentration. The developed PBPK model with information on SFs would accelerate translational research in drug development by predicting pharmacokinetics in CKD patients.
INTRODUCTION
Chronic kidney disease (CKD) is a worldwide public health problem with global increase in the number of patients (1, 2) . CKD is associated with multiple physiological changes and, hence, alters the pharmacokinetics (PK) of drugs, which could cause adverse effects (3) (4) (5) . According to the survey of new molecular entities approved from 2003 to 2007 by the US Food and Drug Administration (FDA), half of the orally administered compounds with altered drug disposition in patients with renal disease were predominantly eliminated by non-renal pathways such as hepatic metabolism or biliary excretion (6) . In 2010, the FDA issued a draft guidance emphasizing the need to perform clinical studies on drugs that are eliminated by non-renal mechanisms as well as the renal route in patients with renal impairment (7) . For pharmaceutical industries, quantitative prediction of the impact of CKD on drug disposition has become important for the optimal design of clinical studies in patients including careful dosage adjustment to avoid possible side effects.
Recently, physiologically based pharmacokinetic (PBPK) modeling and simulation has increasingly gained importance to provide a rational design for first-in-human studies (8) . PBPK modeling is, generally, constructed based on a bottomup approach, which needs a large number of input parameters such as plasma protein binding and metabolic intrinsic clearance (CL intH ), in addition to physicochemical properties and physiological parameters. With regard to hepatic failure, quantitative variations in the activity or content of cytochrome P450 (CYP) enzymes have been reportedly available alongside alternation of physiological parameters, and such information are successfully applied to PBPK models to describe the PK in liver cirrhosis (9, 10) .
On the other hand, the effects of chronic renal failure (CRF) on PK have been evaluated mainly in animal models (11, 12) . Based on the accumulated evidence from in vitro and in vivo studies, the mechanisms underlying the alternation of PK can be explained as follows (3, 4) : uremic toxins such as indoxyl sulfate, parathyroid hormone, and cytokines, all of which are highly increased in the serum of chronic renal failure patients, are involved in either the transcriptional or Electronic supplementary material The online version of this article (doi:10.1208/s12248-014-9626-3) contains supplementary material, which is available to authorized users.
translational modifications or direct inhibition of CYP enzymes or transporters. The elevated concentrations of parathyroid hormone in chronic renal failure lead to the down-regulation of hepatic drug-metabolizing enzymes including CYP enzymes through activation processes like nuclear factor-κB. Since various mechanisms are complexly intertwined, it is difficult to quantitatively evaluate these parameters in CKD condition, which are necessary for the bottom-up approach, based on in vitro systems and in vivo animal models for individual drugs.
Meanwhile, the top-down approach, which is based on the actual changes in PK parameters derived from clinical data, would become a useful tool to predict drug dispositions in CKD patients by the PBPK model. Rowland et al. quantitatively estimated the microsomal content of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 enzymes in CKD condition (13) , by the back calculation of in vivo hepatic clearance (CL H ) to CL intH including the correction of differences in plasma protein binding, and predicted the PK of paroxetine, diltiazem, and repaglinide in patients. The same input parameters for CYP enzyme abundance in CKD condition were also utilized by Zhao et al., who prepared an expanded PBPK model by incorporating the hepatic uptake process (14) . Furthermore, the simulation of the changes in plasma concentrations of solifenacin in CKD patients employed a factor of 0.6, which was estimated from the difference in in vivo clearance (CL) between healthy volunteers (HV) and CKD patients (15) . Although these PBPK models informed by the top-down approach allow successful predictions of PK in CKD patients for certain drugs, the reduction of CL intH or in vivo CL in CKD patients in these models is derived from a limited number of clinical studies.
Importantly, taking complex mechanisms into consideration, a relatively large dataset encompassing an equally large number of drugs is essentially required for the top-down approach, and the change ratios of PK parameters obtained from the differences between CKD patients and HV should be applied as scaling factors (SF) to the prediction of the plasma concentrations in the PBPK model. In the present study, we extensively collected clinical data of CKD patients for a variety of drugs that are non-renally and/or renally eliminated, and the utility of the obtained SFs in the PBPK model was evaluated by comparing the predicted and observed changes in PK parameters and plasma concentration profiles in CKD patients.
MATERIALS AND METHODS

Data Collection
The clinical data for 151 compounds, for which PK parameters in HV and both moderate and severe CKD patients were available, were collected from the literature or the PharmaPendium database (Elsevier, NY, USA; https://www.pharmapendium.com/). Moderate and severe CKD are generally defined by a glomerular filtration rate (GFR); 30 to 59 mL/min/1.73 m 2 for moderate and 15 to 29 mL/min/1.73 m 2 for severe CKD. The collected PK parameters were as follows: unbound fraction in plasma (f p ), fraction excreted unchanged in urine (f e ), an apparent volume of distribution at a steady state (V ss ), CL, area under the plasma concentration-time curve (AUC) after oral dosing, and the elimination half-life (t 1/2 ). These data were summarized as supplemental data (Supplementary  Table S1 ). In silico parameters such as lipophilicity (clogP), pH-dependent measure of lipophilicity (clogD), and basic and acidic dissociation constants (pK a ) were calculated from structural information using CLOGP, version 4.82 (Daylight Chemical Information Systems Inc., CA, USA) and Pallas, version 4.4.1 (CompuDrug Inc., AZ, USA). The compounds were divided into acidic, basic, and neutral classes based on the differences between the clogD values at pH 6.5 and 7.4 (ΔclogD) as indicated by the following equation:
Compounds with positive and negative ΔclogD values were classified as acidic and basic, respectively. Compounds with ΔclogD values of zero were assumed to be neutral. As blood to plasma concentration ratio (R B ) values of most compounds were not available from the literature data, they were assumed to be 0.6 for acidic compounds and 1 for the other, basic and neutral, compounds (16) (17) (18) . Unbound fraction in blood (f B ) was calculated by dividing f p by R B . The information on hepatic elimination mechanisms including the contribution of CYP enzymes was obtained from the literature or FDA approval packages.
Dataset for the Evaluation and Prediction of CL Alterations
To evaluate the alteration of unbound CL intH (CL UintH ) in disease conditions, the 1st dataset was used as a training set. The 1st dataset consists of PK data after oral administration for 76 compounds that are mainly eliminated via the hepatic route (f e <0.4; averaged value, 0.05). Then, the SF for CL UintH obtained from the 1st dataset was applied to the well-stirred model together with those for f p and renal blood clearance (CL R ), and predictabilities for CLs in CKD conditions were confirmed using the 2nd dataset as a validation set. The 2nd dataset, which is independent from the 1st dataset, consists of intravenous data of 40 compounds eliminated via both renal and non-renal routes (averaged f e value, 0.50). In addition, within the 2nd dataset, the compounds, for which plasma concentrationtime profiles were available, were used for the validation of a PBPK model combined with the SFs in CKD patients. The summary of 1st and 2nd datasets was shown in the supplemental data (Supplementary Table S2 ).
Alterations of the PK Parameters in CKD Patients
Collected f p and V ss in patients with moderate and severe CKD were compared with those in HV to produce the relative percentages (RP) for each disease stage as shown in the following equation:
CL R was obtained from the literature information or calculated from plasma CL after intravenous dosing as shown in the following equation:
The CL R in patients with moderate and severe CKD was compared with those in HV, and the RPs in each disease stage were obtained in the same manner as f p and V ss .
For alterations in CL intH , as enough data of intravenous PK profiles in hepatically cleared drugs were not available, RPs were obtained from dose-normalized AUC after oral dosing in the 1st dataset. The theory underlying this calculation was derived from the well-stirred liver model and shown by the following equation:
where Q H is the hepatic blood flow, F a is the fraction moving into enterocytes, F g is the fraction escaping gut-wall elimination, and F h is the fraction escaping hepatic elimination. Assuming that F a , F g , and R B were not altered in the CKD condition, the RP of CL intH was obtained as shown by the following equation: The RPs in CL R and CL UintH were obtained from compounds with f e values of >0.4 (mainly eliminated via the kidney) and <0.4 (mainly eliminated via the liver), respectively.
Prediction of CL in CKD Patients
The predictabilities for CLs in CKD condition were validated with the 2nd dataset. The SF for CL R , f p , and CL UintH in patients with moderate and severe CKD, which represent the relative difference under the disease conditions compared to HV, was obtained as follows. The SF for CL R was defined as the relative changes of GFR ranges under each disease condition. Although GFR is generally defined as a range of 15 to 30 mL/min/1.73 m 2 for severe CKD, the lower limit of 10 mL/min/1.73 m 2 was used for the calculation of SF, because patients with GFR below 15 mL/min/1.73 m 2 were often included in this survey. For HV, a GFR of 125 mL/min/1.73 m 2 was used for calculation (19) . The SFs for f p and CL UintH were assumed to be equal to the interquartile ranges of the RP of each parameter in the disease states obtained in this study. The parameters under disease conditions (CL R,CKD , f p,CKD , and CL UintH,CKD ) were calculated by multiplying those under healthy conditions by the SFs.
To predict CL H under CKD conditions (CL H,CKD ), the following simple well-stirred equation incorporating f p,CKD and CL UintH,CKD was used:
It was assumed that Q H and R B values are not altered under CKD conditions. By combining these CL R,CKD and CL H,CKD , the total CL under the disease condition (CL CKD ) was predicted as expressed by the following equation:
Prediction of Plasma Concentrations in CKD Patients
Within the 2nd dataset, the compounds, for which plasma concentration-time profiles after intravenous dosing were available, were used for the validation of a PBPK model combined with the SFs in CKD patients. The structure of the PBPK model and physiological parameters used are shown in Supplementary Fig. S1 and Supplementary Table S3, respectively. The framework of the PBPK model had previously been reported (20) , that is, the model is composed of 11 tissue compartments (lungs, adipose tissue, bones, brain, heart, muscles, kidneys, spleen, liver, skin, and small intestine), which are linked by venous and arterial blood pools. Perfusion ratelimited kinetics were assumed, and each tissue was represented by a single well-stirred compartment. The liver and kidney were considered as the elimination sites. The principles of mass balance equations for non-eliminating tissues, liver, and kidney are indicated by the following differential equations:
where V is the volume, Q is the blood flow, C is the concentration, K p is the tissue to plasma concentration ratio, and for subscripts, T is for tissue, a is for artery, H is for hepatic, SP is for spleen, SI is for small intestine, and R is for renal.
Firstly, the PBPK model was constructed using the observed f p , CL UintH , and CL R to simulate the plasma concentration-time profiles after intravenous dosing in HV. The K p values for HV in each tissue was calculated by the tissue composition-based equations proposed by Rodgers et al. (21, 22) , using clogP, pK a , and f p . A uniform factor obtained from the comparison of the predicted and observed V ss was applied to the calculated K p values for the adjustment of PK profiles in HV (20) . The SFs for f p , CL UintH , and CL R were then introduced to obtain the parameters under CKD conditions, and the plasma concentrations in patients were simulated. Note that the K p values of CKD patients were recalculated by the same procedure using f p,CKD .
The PK parameters (V ss , CL, and t 1/2 ) were estimated by the non-compartmental analysis of simulated plasma concentrations in both HV and patients, and RP of these parameters in disease states were calculated. Model construction, simulation of plasma concentrations, and non-compartmental analysis were performed by Phoenix WinNonlin, version 6.3 (Pharsight, CA, USA).
RESULTS
Alterations of f p and V ss in CKD Patients
The RPs of f p and V ss in CKD patients compared with HV are shown in Fig. 1 and are summarized in Table I . For acidic and neutral compounds, the f p increased in CKD patients with the median RP of 109 to 115% for moderate and 134 to 135% for severe CKD, indicating that the extent of change in the f p depended on the progression of disease. On the contrary, the f p for basic drugs showed no significant changes with the median RP of 99 to 104%. For the V ss , no pronounced differences between the disease states or drug properties were observed with the median RP of 95 to 107%. The interquartile ranges of the RP for the obtained f p in each class of drug presented in Table I were used as the SFs for the prediction of CL, CL R , CL H , and PK in CKD patients. Given that the alteration of V ss was not found under any disease conditions and the V ss was generally determined by the f p and physicochemical properties in PBPK models, the SF of V ss was not taken into consideration for PK prediction.
Alteration of CL R in CKD Patients
The RPs of CL R in CKD patients compared with HV are shown in Fig. 2 and Table II. The CL R showed a disease statedependent reduction with median RP of 31% for moderate a b Fig. 1 . RP of f p (a) and V ss (b) in moderate and severe CKD. In the boxes, the middle lines represent the median values, the top and bottom margins represent the 75th and 25th percentiles, and the top and bottom whiskers represent the 90th and 10th percentiles. The percentages on the right of the boxes represent median values and 12% for severe CKD. The alterations in CL R were within the range of change for GFR (24 to 47% for moderate and 8 to 23% for severe CKD). Compounds with lower and higher unbound CL R (CL R /f B ) than GFR, which can be considered to be predominantly eliminated by glomerular filtration and tubular secretion, respectively, showed similar changes in the CL R , as determined by the median RP of 35 versus 31% for moderate and 13 versus 11% for severe CKD. This finding indicated that the alterations in CL R can be predicted based on the GFR regardless of the elimination mechanism. Therefore, instead of the interquartile ranges of the RP of CL R , the ranges of GFR to be defined in moderate and severe CKD were applied as the SF for the prediction of CL R and PK in CKD patients.
Alteration of CL UintH in CKD Patients
The RPs for CL UintH in CKD patients compared with HV were obtained from the 1st dataset and are shown in Fig. 3 and Table II . In both disease stages, a similar extent of decrease in CL UintH was noted for CYP and UDP-glucuronosyltransferase (UGT) substrates and drugs eliminated via other mechanisms, with the median RP of 67 to 68% in moderate and 59 to 65% in severe CKD conditions. The change in CL UintH was unlikely dependent both on the disease stage of CKD and the elimination mechanism in the liver. Consequently, the median RP of CL UintH for all examined drugs was calculated as 68% (interquartile range, 55 to 82%) in moderate and 62% (interquartile range 48 to 80%) in severe CKD, and these interquartile ranges were used as the SFs for the following predictions of CL H and PK in CKD patients.
Prediction of CLs in CKD Patients
The present study demonstrated that there were relatively large variations in the alterations of CL R and CL H between the examined compounds, and therefore, CLs in the 2nd dataset were predicted using SFs based on the interquartile ranges analyzed for the CL UintH and f p . The SFs for CL R , CL UintH , and f p used in the present study are summarized in Table III . The predicted and observed mean RP of CL R , CL H , and CL in CKD patients compared with HV and the success rates of the prediction are shown in Table IV vs 43% in severe CKD). When the range of the predicted CLs included the observed data, the prediction was defined to be successful. The percentages of compounds that were successfully predicted were 66 to 70% for CL R , 47 to 48% for CL H , and 67 to 68% for CL.
Prediction of Plasma Concentrations in CKD Patients
The plasma concentration-time profiles after intravenous dosing of 12 model compounds in HV, moderate, and severe CKD were simulated by the PBPK model incorporating the SFs under the disease conditions. The predicted range and mean observed RP for CL, V ss , and t 1/2 in CKD patients are summarized in Table V . The simulated plasma concentrationtime curves of six drugs (the best and worst predicted compounds in each group; mainly eliminated via the renal, non-renal, and mixed routes) are also described in Fig. 4 . In case the range of the predicted parameters included the observed values, the compounds were classified as showing successful prediction. For the CL prediction in CKD patients, 10 (83%) and 7 (58%) of 12 compounds were regarded to show successful prediction in moderate and severe CKD, respectively. The alterations of t 1/2 in CKD patients were also well-predicted by the PBPK model, accompanied with successful predictions in 9 (75%) and 8 (67%) of 12 compounds under moderate and severe CKD conditions, respectively.
DISCUSSION
In the present study, we extensively collected clinical data of 151 compounds with various pharmacokinetic properties and analyzed the impact of CKD on different PK parameters. Notably, for altered hepatic elimination, clinical data of over 70 compounds were comprehensively analyzed. The CL UintH of compounds that are eliminated via hepatic metabolism by CYP, UGT, or other mechanisms decreased to a similar extent in CKD patients as to HV. CL R showed a similar decrease to GFR irrespective of the involvement of tubular secretion. The RP in each parameter under different disease conditions showed large variations, which might involve a variety of mechanisms. Therefore, SFs based on the interquartile range estimated by a statistical analysis of the RP were applied to the well-stirred model to predict the CLs in CKD patients. CL H and CL R were successfully predicted for approximately half and two-thirds of the compounds, respectively. Importantly, the SFs for CL UintH obtained from the 1st dataset were validated using the different datasets (the 2nd dataset) in the prediction of CLs. The plasma concentration-time curves of 12 model compounds in CKD patients were also well-predicted by the application of the SFs into the PBPK model, as demonstrated by the relatively high success rates for CL and t 1/2 .
During the drug development stage, a perspective evaluation for the influence of CKD on the PK of new molecular entities has become a critical issue for the pharmaceutical industries. Since multiple factors are complexly intertwined in the alteration of the PK under CKD conditions, we employed the top-down approach rather than the bottom-up approach based on in vitro and in silico data. Some authors have proposed PBPK models incorporating the CL UintH reduction in CKD patients based on the top-down approach; however, these models were derived from a limited number of clinical data (13) (14) (15) . On the other hand, one advantage of this study is that SFs based on an interquartile range derived from a relatively large number of clinical data are employed and would have a possibility for encompassing widely ranging PK alterations by various mechanisms in CKD.
Plasma protein binding is a governed factor to PK behavior and is known to vary depending on the plasma concentrations of the binding proteins as well as several other factors in CKD patients such as the competition of the binding sites by metabolites that have accumulated as a result of reduced renal function or the denaturation of albumin itself due to uremic toxins (23) . Strougo et al. demonstrated that the albumin plasma concentration tended to decrease, but the median α 1 -acid glycoprotein level in the plasma was 1.4 times higher in patients with moderate to severe CKD compared to the control group (15) . In this study, acidic and neutral compounds clearly exhibited an increase in f p in patients with severe CKD probably due to a decrease in the plasma concentration of albumin to which these classes of compounds mainly bind (24) . Regarding basic compounds, it CL  34  52  54  68  12  21  CL R  32  43  36  66  22  13  CL H  33  73  75  48  18  33  Severe  CL  36  43  45  67  8  25  CL R  33  21  16  70  21  9  CL H  34  69  79  47  15  38 The predictabilities for CLs were evaluated using the 2nd dataset CKD chronic kidney disease, RP relative percentage, CL clearance, CL R renal blood clearance, CL H hepatic clearance a The predicted range included the observed change b The predicted range was greater than the observed change c The predicted range was smaller than the observed change was assumed that f p would decrease if the α 1 -acid glycoprotein plasma level increases in severe CKD in theory; but in practice, the f p of some compounds almost remained constant or increased in moderate and severe CKD, which is probably due to multiple mechanisms. Importantly, V ss was almost consistent for all of the examined compounds regardless of the increase of f p in acidic and neutral drugs possibly because these classes of compounds have relatively small distribution volume which is not sensitive to the alteration of plasma protein binding. In general, the renal tubular secretion is reportedly known to involve various transporters including organic anion transporters 1 (OAT1) and 3 (OAT3), organic cation transporter 2 (OCT2), and multidrug resistance protein 2 (MRP2) (25) . An animal study using CRF rats demonstrated the alteration of hepatic and intestinal protein expression levels of multidrug resistance 1 (MDR1) and MRP2 (4). However, there is no literature on the up-or down-regulation of proteins or mRNA expression levels of those transporters in the kidneys of CKD patients. Interestingly, the impact of CKD on glomerular filtration and on renal tubular secretion was not different, and the RP of CL R for compounds that undergo tubular secretion was proportional to GFR. This finding provides insight into CL R prediction, namely that GFR is still a dominant factor to predict CL R regarding renal tubular secretion in addition to glomerular filtration.
Unexpectedly, the percentage reduction of CL UintH in CKD patients relative to that in HV was not affected by the disease progress and was within a similar range for CYP and UGT substrates. The result was in agreement with the findings reported by Zhang et al., who showed that there were no significant differences in the AUC changes between CYP and non-CYP substrates in CKD patients (6) . In addition, the RPs of CL UintH for typical substrates of CYP1A2, CYP2C9, and CYP3A did not differ in CKD patients except for CYP2D6 that slightly showed the lower RP (data not shown). Rowland et al. also evaluated the RPs for CYP1A, CYP2C9, CYP2D6, and CYP3A4 (13) . The estimated RPs were decreased by the progression of the disease and appeared to be slightly lower than the corresponding median data in our study. In hepatocytes prepared from rats with CRF, down-regulation was found for CYP2C11 and CYP3A1/2, but not for CYP1A2 and CYP2D proteins (26) . There may be species differences in the down-regulation of CYP enzymes between humans and rats. It has not yet been attempted to investigate a change in UGT expression level by the CRF condition in preclinical studies.
One of our objectives of this study was to acquire SFs based on a relatively large amount of clinical data to develop a universal prediction model by the top-down approach. To increase the number of compounds, the RP for the reduction of hepatic elimination was estimated from the oral AUC, which was in contrast to Rowland's method using a small number of intravenous PK data (13) . The alterations of CL UintH under CKD conditions were evaluated assuming that the F a and F g are not affected by CKD. The F a and F g are controlled by passive absorption, transporter-mediated influx and efflux, and metabolism mainly by CYP3A in humans. It has been reported that P-glycoprotein and some CYP enzymes including CYP3A are down-regulated in the small intestine of animal models of CRF (27, 28) , which leads to the increase of F a and F g in the disease condition. CYP3A substrates among our dataset were regarded as relatively high F h compounds, and this implied that F g of these compounds
were also high and that the effect of the alternation of F g on the estimation of SF was limited. It is important to note that the applicability of SFs derived from the oral AUC was proven by a relatively high success rate for CL in different datasets after intravenous dosing, which shows a minor effect of the alterations of F a and/or F g on RPs' estimation. In this study, however, as PK alterations of midazolam, which is known as the typical substrate of CYP3A with a significant intestinal first-pass metabolism (29), could not be evaluated because both moderate and severe CKD data were not separately available, further discussion would be needed for the effect of the alteration of F g in the disease conditions. Another assumption in obtaining the SF for CL UintH is that R B value does not change in the disease condition. Since R B is a function of f p which increased by up to approximately 50% in neutral drugs in the disease condition, the alteration of R B could have an impact on the determination of SF for CL UintH . However, relatively high plasma protein binding of drugs in the 1st dataset (averaged value of known f p , 0.11) indicated low distribution to blood cell, and the impact of the change of R B on SF seems to be minor. In addition, regarding compounds that strongly bind to α 1 -acid glycoprotein, the change of f p due to increased plasma binding protein level in the disease condition would give an impact to SF for CL UintH . Further analysis on the alteration of f p in patients would be required for such compounds.
Some drugs are known to be mainly eliminated via hepatic transporters such as organic anion transporting polypeptides (OATPs) (30) , but the number of such compounds included in the current dataset was so limited. Consequently, the estimated SF is unlikely to reflect a change in the hepatic uptake activity; hence, the insufficient dataset for the liver uptake via transporters could be one of the reasons for the over-prediction of CL.
The PBPK model with SFs based on an interquartile range estimated in the present study was used for the simulation of the plasma concentration profiles of 12 model compounds with widely ranging f e values. Consequently, the plasma concentrations of the 12 model drugs seemed to coincide with the observed data, and this was supported by a relatively high accuracy of CL and t 1/2 , which were successfully predicted for 58 to 83% and 67 to 75% compounds, respectively, in CKD patients. These data suggest the utility of SFs with an interquartile range on PK prediction in CKD patients of drugs eliminated by different pathways. For the prediction of V ss , only two compounds in each moderate and severe CKD condition were successfully predicted. Since the prediction of V ss is based on the alteration of f p in the PBPK model, an improved prediction method of f p in disease condition would lead to a better predictability of V ss .
More recently, translational research, which involves the translation of efficacy and PK data from preclinical to clinical studies via modeling and simulation cycles, occupies an important position in drug development (31, 32) . We have proposed the tiered approach, which consists of four steps based on modeling and simulation of PBPK models to predict human PK from drug discovery to first-in-human studies (20) . In the last step, the measured plasma concentration profile in HV allows us to optimize the PBPK model by the integration of comprehensive in vitro and in vivo information. Such a PBPK model developed through modeling and simulation would become a key tool to evaluate intrinsic factors (age, gender, race, disease, and genetic polymorphism) on human PK in clinical studies. In the draft guidance, FDA recommends that pharmaceutical companies conduct either "the reduced PK study" in end-stage renal disease patients or "the full PK study" for more detailed evaluation in mild, moderate, and severe CKD patients to assess the possible impact of CKD on drug disposition under development (7) . The new method with SFs derived by the top-down approach would provide a rationale for the selection of the appropriate study as well as dose adjustment through predicting the PK profile in patients from that in HV and also accelerates the implementation of model-based drug development that is deeply associated with decision-making based on PK profile prediction and risk assessment of toxicity.
CONCLUSION
We collected the large dataset regarding PK parameters in CKD patients and comprehensively described large variations in the alterations in PK parameters. Consequently, the SFs with an interquartile range were successfully derived from PK parameters in the disease conditions by the topdown approach. The predictability of the PBPK model combined with the SFs was validated using 12 model compounds with various PK profiles. The developed PBPK model with information on SFs would play an important role in the translational research in drug development.
